What's the (end) point of cancer vaccines?

Expert Review of Anticancer Therapy

Volumn 6, Issue 8, 2006, Pages 1133-1149

  Bower, Mark ^a   Mazhar, Danish ^a   Stebbing, Justin ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; CANVAXIN; CEAVAC; CYCLOPHOSPHAMIDE; DACARBAZINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GV 1001; HORMONE; IMMUNOSUPPRESSIVE AGENT; INSEGIA; L BLP 25; LIPONOVA RENIAL; LUCANIX; M VAX; MELACINE; MITUMOMAB; MITUMONAB; MYVAX; ONCOVAX; PANVAC; PROSTVAC; PROVENGE; STIMUVAX; TEMOZOLOMIDE; THERATOPE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL TRANSFORMATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; KAPOSI SARCOMA; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCREAS CANCER; PROSTATE CANCER; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR IMMUNITY;

CANCER VACCINES; CLINICAL TRIALS; HUMANS; IMMUNIZATION; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 33748125388     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.8.1133     Document Type: Editorial

References (23)

1. Sulek K. Prize in 1908 awarded to P Ehrlich and E Metchnikoff for their work in immunology. Wiad. Lek. 20, 1117-1118 (1967).
2. Ehrlich P. The partial function of cells: Nobel prize address given on 11 December 1908 at Stockholm. Int. Arch. Allergy Appl. Immunol. 5, 67-86 (1954).
3. Siegel JH, Janis R, Alper JC, Schutte H, Robbins L, Blaufox MD. Disseminated visceral Kaposi's sarcoma. Appearance after human renal homograft operation. JAMA 207, 1493-1496 (1969).
4. Myers BD, Kessler E, Levi J, Pick A, Rosenfeld JB, Tikvah P. Kaposi sarcoma in kidney transplant recipients. Arch. Intern. Med. 133, 307-11 (1974).
5. Penn I. Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation 27, 8-11 (1979).
6. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N. Engl. J. Med. 348, 1681-1691 (2003).
7. Stebbing J, Bower M. What can oncologists learn from HIV? Lancet Oncol. 4, 438-445 (2003).
8. Klein G, Sjorgen HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1562 (1960).
9. Klein G. Tumor antigens. Annu. Rev. Microbiol. 20, 223-252 (1966).
10. Burnet FM. Immunological aspects of malignant disease. Lancet 1, 1171-1174 (1967).
11. Burnet FM. Immunological surveillance in neoplasia. Transplant Rev. 7, 3-25 (1971).
12. Bayer R, Oppenheimer GM. AIDS Doctors, Voices from the Epidemic: an Oral History. Oxford University Press, Oxford, UK (2002).
13. Stebbing J, Portsmouth S, Bower M. Insights into the molecular biology and sero-epidemiology of Kaposi's sarcoma. Curr. Opin. Infect. Dis. 16, 25-31 (2003).
14. Stebbing J, Bower M, Srivastava P. Kaposi's sarcoma as a model for cancer immunotherapy. Trends Mol. Med. 10, 187-193 (2004).
15. Whelan M, Whelan J, Russell N, Dalgleish A. Cancer immunotherapy: an embarrassment of riches? Drug Discov. Today 8, 253-258 (2003).
16. Ward S, Casey D, Labarthe MC et al. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 51, 351-357 (2002).
17. Finn OJ. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3, 630-641 (2003).
18. Dalgleish AG, Whelan MA. Cancer vaccines as a therapeutic modality: the long trek. Cancer. Immunol. Immunother. 55, 1025-1032 (2006).
19. Slingluff CL Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin. Cancer Res. 12, S2342-S2345 (2006).
20. Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin. Cancer Res. 12, S2337-S2341 (2006).
21. Labarthe MC, Halanek N, Birchall L et al. The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model. Cancer. Immunol. Immunother. 55, 277-288 (2006).
22. Schnittger S, Schoch C. Quantitative PCR based minimal residual disease detection in core binding factor leukemias: prognostication and guiding of therapy. Leuk. Res. 30, 657-658 (2006).
23. Ireland R. Multimarker RT-PCR for detection of minimal residual disease in breast cancer patients. Nat. Clin. Pract. Oncol. 3, 293 (2006).